Mary Dickinson Chamberlin MD

Oncology•Lebanon, NH

Associate Professor, Medicine, Geisel School of Medicine

Join to View Full Profile

1 Medical Center DrDartmouth-Hitchcock Medical Center - NcccLebanon, NH 03756
Phone+1 603-653-6181

Education & Training

Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalFellowship, Hematology and Medical Oncology, 2004 - 2006
University of Vermont Medical CenterResidency, Internal Medicine, 2000 - 2003
University of Vermont College of MedicineClass of 2000

Certifications & Licensure

VT State Medical License 2000 - 2026
NH State Medical License 2003 - 2025
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
ACTIVE_NOT_RECRUITING
PHASE3
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
ACTIVE_NOT_RECRUITING
PHASE3
Low Dose Chemotherapy With Aspirin in Patients With Breast Cancer After Neoadjuvant Chemotherapy Start of enrollment: 2011 Feb 01
Unknown status
Not Applicable
Effect of a Goal Setting Intervention on Exercise in Women With Metastatic Breast Cancer: An Exploration of The Lipogenic Pathway Start of enrollment: 2012 Dec 01
Terminated
Not Applicable
BKM120 for Patients With PI3K-activated Tumors Start of enrollment: 2013 Mar 29
Completed
Phase 2
Developing Plasma DNA as a Surrogate for Tumor Biopsy to Identify Tumor Genetic Alterations in Patients With Advanced Breast Cancer Start of enrollment: 2013 Dec 01
Terminated
Genetically-informed Therapies for Patients With Metastatic Cancer Start of enrollment: 2014 Jan 01
Withdrawn
Phase 4
A Randomized, Controlled Trial to Determine the Effects of an Exercise Intervention on Physical Activity During Chemotherapy for Patients With Early Stage Breast Cancer Start of enrollment: 2014 Jun 01
Completed
Not Applicable
Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X) Start of enrollment: 2016 Feb 25
Withdrawn
Phase 2
Phase II Study of Neoadjuvant ArOMatase Inhibitor Therapy for ER+ Breast Cancer (NAOMI) Start of enrollment: 2021 Aug 13
RECRUITING
PHASE2
Join now to see all

Publications & Presentations

PubMed

Oxidative Phosphorylation Is a Metabolic Vulnerability of Endocrine Therapy-Tolerant Persister Cells in ER+ Breast Cancer.
Steven Tau, Mary D Chamberlin, Huijuan Yang, Jonathan D Marotti, Patricia C Muskus
Cancer Research. 2025-03-14
Resolution of Pyoderma Gangrenosum During Adjuvant Breast Cancer Therapy.
Abigail P Lauder, Anita Nwiloh, Matthew Eximond, Robert E LeBlanc, Alicia T Dagrosa
Journal of Clinical Medicine. 2025-02-17
Prevalence of Human Papillomavirus-Associated Head and Neck Cancer in Rwanda: A 10-Year Review.
Fidel Rubagumya, Lydia Businge, Wilma H Hopman, Gad Murenzi, Aline Uwimbabazi
Cancer Medicine. 2024-11-01

Press Mentions

Virginia Department of Health to Open Community Vaccination Center in Fredericksburg for Booster ShotsOctober 14th, 2021
COVID Hospitalizations Double in Stafford County in 5 DaysAugust 3rd, 2021
Northern Virginia Counties Promote Vaccines as Rates StallJuly 26th, 2021
Join now to see all

Mary Dickinson Chamberlin MD

Dr. Chamberlin is on Doximity

Education & Training

Certifications & Licensure

Awards, Honors, & Recognition

Clinical Trials

Publications & Presentations

Press Mentions

Viewing the full profile is available to verified healthcare professionals only.